AGER Polyclonal Antibody

Background
Mediates interactions of advanced glycosylation end products (AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling By similarity. Receptor for amyloid beta peptide. Contributes to the translocation of amyloid-beta peptide (ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons. ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase (MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space.

Description
AGER Polyclonal Antibody. Unconjugated. Raised in: Rabbit.

Formulation
0.03% Proclin 300. 50% Glycerol, 0.01M PBS, pH 7.4.

Specificity
Human

Isotype
IgG

Uniprot ID
Q15109

Purification
Protein G purified

Immunogen
Recombinant Human Advanced glycosylation end product-specific receptor protein (23-342AA)

Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C (short-term) or -80°C (long-term). Avoid repeated freeze.

Alternative Names
Receptor for advanced glycosylation end products, AGER, RAGE

Application
ELISA, IHC, IF; Recommended dilution: IHC:1:20-1:200, IF:1:50-1:500